hengrui glp 1 In a Phase 3 program reported by Kailera Therapeutics and partner Jiangsu Hengrui, two China trials of the oral small-molecule GLP-1 receptor agonist HRS-7535 met their primary goals in obesity and in Hengrui's GLP-1/GIP agonist posts 18%
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2


























